New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
12:40 EDTVVUS, OREX, ARNAVIVUS retreats after analyst cuts rating to sell equivalent
Shares of VIVUS (VVUS), which has developed an anti-obesity drug, are declining after research firm Piper Jaffray downgraded the stock in a note to investors earlier today. WHAT'S NEW: Piper analyst Charles Duncan wrote that he was "increasingly wary" about the outlook for VIVUS' anti-obesity drug, Qsymia. Prescription trends for the drug are "underwhelming," while VIVUS has so far failed to find a U.S. marketing partner for the drug, the analyst explained. Moreover, a competing anti-obesity drug, Orexigen's (OREX) Contrave, is expected to be launched in the second half of this year, Duncan wrote. He now expects VIVUS to generate revenue of $53M for Qsymia, versus what he said was the consensus outlook of $92M. Duncan cut his rating on the stock to Underweight, the equivalent of a sell, from Neutral and slashed his price target on the shares to $3 from $8. WHAT'S NOTABLE: Despite the downgrade, Duncan wrote that he continues to believe the U.S. anti-obesity market outlook is improving. Arena Pharmaceuticals (ARNA) has also developed an anti-obesity drug. Belviq. PRICE ACTION: In early afternoon trading, VIVUS fell 8% to $5.70, Orexigen dropped 4.3% to $6.20, and Arena fell 3.6% to $6.45.
News For VVUS;OREX;ARNA From The Last 14 Days
Check below for free stories on VVUS;OREX;ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
08:06 EDTOREXOrexigen receives Day 180 List of Outstanding Issues from EMA
Subscribe for More Information
08:04 EDTARNAArena Pharmaceuticals and Eisai announce results of Lorcaserin Phase 2 trial
Arena Pharmaceuticals and Eisai announced that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin was recently published in the official peer reviewed journal of The Obesity Society. The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin. Belviq is a serotonin 2C receptor agonist approved in the U.S. as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese or overweight adults with at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
July 29, 2014
08:19 EDTARNAArena Pharma' and Eisai announce nomination of BELVIQ by Gallen Foundation
Eisai and Arena Pharmaceuticals (ARNA) announced that BELVIQ, or lorcaserin HCl, has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013.
July 25, 2014
11:22 EDTOREXOptions with increasing implied volatility: OREX TLM IP BG
Subscribe for More Information
July 21, 2014
10:31 EDTOREXHigh option volume stocks:
High option volume stocks: EZPW LCI STLD SIAL FL OREX CROX NIHD EXTR BBT
08:11 EDTARNAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use